114 related articles for article (PubMed ID: 6896222)
21. Thyroid function in patients with Graves' disease long after 131I therapy.
Inoue K; Okamura K; Shiroozu A; Nakashima T; Yoshinari M; Omae T; Nishitani H
Fukuoka Igaku Zasshi; 1980 Jul; 71(7):408-16. PubMed ID: 6894288
[No Abstract] [Full Text] [Related]
22. Five years' experience with iodine-125 therapy of Graves' disease.
Weidinger P; Johnson PM; Werner SC
Lancet; 1974 Jul; 2(7872):74-7. PubMed ID: 4136737
[No Abstract] [Full Text] [Related]
23. Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.
Burman KD; Dimond RC; Earll JM; Wright FD; Wartofsky L
J Clin Endocrinol Metab; 1976 Sep; 43(3):606-13. PubMed ID: 989049
[TBL] [Abstract][Full Text] [Related]
24. Graves' disease after 131I therapy for toxic nodule.
Soule J; Mayfield R
Thyroid; 2001 Jan; 11(1):91-2. PubMed ID: 11272103
[No Abstract] [Full Text] [Related]
25. Short and long term effects of radioiodine treatment on the iodine content of the thyroid gland.
Schlumberger M; Fragu P; Hill C; Parmentier C; Tubiana M
J Clin Endocrinol Metab; 1984 Nov; 59(5):893-8. PubMed ID: 6548226
[TBL] [Abstract][Full Text] [Related]
26. Acquired refractoriness to thyroid hormone action in treated toxic nodular goiter.
Sterling K; Aranow H
JAMA; 1981 Apr; 245(13):1339-40. PubMed ID: 6894170
[TBL] [Abstract][Full Text] [Related]
27. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease.
Bogazzi F; Bartalena L; Campomori A; Brogioni S; Traino C; De Martino F; Rossi G; Lippi F; Pinchera A; Martino E
J Clin Endocrinol Metab; 2002 Oct; 87(10):4490-5. PubMed ID: 12364424
[TBL] [Abstract][Full Text] [Related]
28. [Plasmatic thyroid hormones during treatment of hyperthyroidism by carbimazol (author's transl)].
Linquette M; Lefebvre J; Benoit G; Racadot A
Ann Endocrinol (Paris); 1977; 38(2):169-70. PubMed ID: 578398
[TBL] [Abstract][Full Text] [Related]
29. [Endocrine ophthalmopathy in Graves disease during antithyroid drug therapy (author's transl)].
Wuttke H; Schlieter D; Krück F
Klin Wochenschr; 1979 Jan; 57(2):69-74. PubMed ID: 84095
[No Abstract] [Full Text] [Related]
30. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
[TBL] [Abstract][Full Text] [Related]
31. Abnormalities of hypothalamo-hypophyseal-thyroid axis in patients with Graves' ophthalmopathy.
Chopra IJ; Chopra U; Orgiazzi J
J Clin Endocrinol Metab; 1973 Dec; 37(6):955-67. PubMed ID: 4201831
[No Abstract] [Full Text] [Related]
32. Thyroid gland suppressibility in patients treated with radioiodine for diffuse toxic goiter.
Burgos FL; Micames C; Rivera JV
Bol Asoc Med P R; 1983 Apr; 75(4):173-5. PubMed ID: 6575791
[No Abstract] [Full Text] [Related]
33. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
34. [Long-term results of radioiodine (131I) treatment in 331 patients with Graves' disease (author's transl)].
Saito S; Sakurada T; Yamamoto M; Yoshida K; Kaise K; Kaise N; Yoshinaga K
Nihon Naika Gakkai Zasshi; 1979 Jul; 68(7):724-32. PubMed ID: 113472
[No Abstract] [Full Text] [Related]
35. Graves' disease associated with elevated serum thyroxine-binding globulin concentrations.
Yabu Y; Amino N; Nakatani K; Ichihara K; Azukizawa M; Miyai K
J Clin Endocrinol Metab; 1980 Aug; 51(2):325-9. PubMed ID: 6772663
[No Abstract] [Full Text] [Related]
36. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
37. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
[TBL] [Abstract][Full Text] [Related]
38. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
[TBL] [Abstract][Full Text] [Related]
39. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
Gamstedt A; Karlsson A
J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
